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Mutations in several subgenomic regions have been implicated in influencing response to interferon therapy;
however, a comprehensive picture of Indian patients was lacking. Based on the viral load and clinical factors,
10 out of 15 patients were found to be complete responders, whereas 5 patients were nonresponders. The
pretreatment viral RNA load of the patients was found to be between 5.20 and 6.13 log10 IU/ml, which
eventually fell to 2.77 log10 IU/ml after 24 weeks of treatment, whereas in the case of nonresponders, the
average was 5.38 log10 IU/ml. In order to study the influence of the hepatitis C virus genotype on the response
to interferon therapy, the 5 untranslated region sequences of the samples were analyzed, which showed that
genotype 3 patients responded better than genotype 1 patients. Additionally, the mutations in the interferon
sensitivity-determining region (ISDR) of the NS5A protein and the double-stranded RNA-activated protein
kinase–eukaryotic initiation factor 2 alpha phosphorylation homology domain (PePHD) of the E2 envelope
protein, before and after treatment, were compared with nonresponder prototype J. Although, no clear
correlation was found in the case of the mutated ISDR, some significant changes in residues were observed in
the PePHD region, which could be helpful in understanding the molecular basis of resistance to therapy.
Interestingly, analysis of the quasispecies variations showed a change in genotype in one sample during
treatment, which might have contributed to the resistance. The results suggest that the mutations in different
regions of the viral genome might have a concerted effect on the response to interferon therapy.
Hepatitis C virus (HCV), a member of the family Flaviviri-
dae, is the primary causative agent of parenterally transmitted
non-A, non-B hepatitis and affects a significant part of the
population worldwide (4). Together with hepatitis B virus, it is
the major cause of severe liver disorders, like chronic hepatitis
and hepatocellular carcinoma. The infecting genotype, the
quasispecies variations, and the viral load have all been sug-
gested to correlate with the disease severity, degree of liver
damage, and response to interferon treatment (9).
HCV is an enveloped virus with a 9,500-nucleotide-long single-
stranded positive RNA genome encoding a single polyprotein,
which is processed by the host cell and virus-encoded proteases
into three major structural proteins and several nonstructural
proteins necessary for viral replication (6, 22). A comparison of
genome and polyprotein sequences of HCV isolates worldwide
led to the identification of six major genotypes, each with several
subtypes (19). Genotypes 1, 2, and 3 are the major types observed
in Japan, Western Europe, and North America; type 4 has been
found in Central and Northern Africa and in the Middle East;
type 5 has been described in South Africa, and type 6 in Southeast
Asia (15).
Several studies have reported the presence of various HCV
genotypes in India, and genotype 3 has been shown to be
prevalent in most parts of the country. Earlier, HCV types 1a,
1b, 2a, 3a, 3b, and 3g were reported in the northern regions of
India (16, 20), whereas genotype 1 was shown to be prevalent
in southern India (24). Recent studies also suggest a similar
pattern in India, with type 3 being the predominant genotype,
followed by type 1 (13, 20, 5), which was further confirmed by
our group (1).
Like other RNA viruses, HCV is genetically heterogeneous
due to a lack of proofreading activity of RNA-dependent RNA
polymerase, which results in the accumulation of nonlethal
mutations during viral replication, leading to quasispecies pop-
ulations that are transmitted to progeny viruses. This high
genetic complexity of quasispecies populations, as well as the
sequence diversity of particular regions of the viral genome, is
believed to be associated with better adaptation to environ-
mental conditions (21).
The sustained virological response (SVR) with alpha inter-
feron (IFN-) monotherapy in patients infected with HCV
genotype 1 was found to be poor. However, the use of pegy-
lated interferon was found to be associated with a significantly
higher SVR (7). The current strategy of combination therapy
using pegylated interferon plus ribavirin (a nucleoside analog)
has been found to have a much higher sustained virological
response (12). Response to therapy varies according to the
viral genotype, as well as potential host and treatment efficacy
factors. It has been shown in India that patients infected with
genotypes 2 and 3 achieve a sustained virological response of
up to 95% to a combination of daily IFN-2b and ribavirin
(10). Similarly, patients worldwide infected with genotype 2 or
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3 achieve a sustained virological response of up to 72%,
whereas those infected with genotype 1 show relatively low
response rates (13%) after 24 weeks of treatment (25, 26).
Though the mechanism of resistance for interferon treatment
in infected patients is not thoroughly understood, it is believed
that both host and viral factors, including several viral genomic
regions, are essential for an effective response to interferon
therapy (17).
Hepatitis C virus nonstructural protein 5A (NS5A) has been
shown to bind to double-stranded RNA-dependent protein
kinase (PKR) and repress its function (8). Interestingly, the
double-stranded RNA-activated protein kinase–eukaryotic ini-
tiation factor 2 alpha (PKR-eIF2) phosphorylation homology
domain (PePHD) of the structural E2 gene has been shown to
interact in vitro with the interferon-inducible cellular PKR (23).
The 12-amino-acid domain of PePHD acts as a pseudosubstrate
for PKR and thus interferes with the inhibitory effect of PKR
on protein synthesis. Mutations in these regions are believed to
influence the response to interferon therapy; however, the
results of different studies are conflicting and not sufficiently
clear. Also, a majority of these studies have been of HCV type
1, which is the prevalent genotype worldwide. In India, al-
though genotype 3 has been shown to be the most prevalent
strain, genotype 1 is frequently observed in HCV-infected pa-
tients in the south. In order to study the comparative responses
to interferon therapy between the patients infected with the
two genotypes, we have analyzed mutations in specific sub-
genomic regions and compiled the results with the respective
viral load and clinical response to interferon therapy to get a
detailed picture of the possible correlation (if any). For this
purpose, mutations within the interferon sensitivity-determin-
ing region (ISDR) and the PePHD region were extensively
analyzed in samples from 15 infected patients. The changes in
the amino acids in these regions during therapy have been
evaluated, along with the other reported studies, to understand
their relevance as a function of response.
MATERIALS AND METHODS
Detection of HCV in patient serum. Serum samples (10 ml) were collected,
using Vacutainers, from HCV-infected patients from the Center for Liver Re-
search and Diagnostics, Hyderabad, India, and were analyzed immediately for
the presence of HCV using a third-generation enzyme immunoassay (EIA 3.0;
Abbott, Chicago, IL) and reconfirmed using reverse transcription-PCR. These
patients were treated by injecting pegylated IFN-2a (1.5 g/kg of body weight)
with ribavarin (800 to 1,000 mg/day) subcutaneously for a period of 24 weeks.
Serum alanine transaminase (ALT), aspartate transaminase (AST), and alkaline
phosphatase (ALP) levels were measured before and after the interferon treat-
ment.
Amplification of subgenomic-region sequences. Isolated HCV RNA from se-
rum was reverse transcribed by using Moloney murine leukemia virus reverse
transcriptase at 42°C for 60 min, and the cDNA obtained was PCR amplified.
The specific primers used to amplify the subgenomic region were as follows: 5
untranslated region (UTR), sense (5GCCAGCCCCCATTGGGG-3) and an-
tisense (5GTTACGTTTGGTTTTTCT); PePHD, sense (5TGCTGCATGCAA
CTGGA) and antisense (5TGCACGTCCACGATGTTC); and ISDR, sense
(5AGCCAGCTGTCTGCGCC) and antisense (3TCGAAAGAGTCCAG).
PCR was carried out for 36 cycles using Taq polymerase; the annealing temper-
ature used was 54°C, and the extension temperature used was 72°C. The PCR-
amplified products were purified and cloned into the pGEM-T easy vector
(Promega). Single recombinant plasmids were sequenced by Macrogen Inc.,
South Korea.
Measurement of HCV viral load. The HCV viral load was assessed using a
commercially available kit, a second-generation hepatitis C virus quantitative
assay (COBAS AMPLICOR HCV Monitor Test, version 2.0) from Roche Di-
agnostic Systems. The detection limit of this kit was 600 IU/ml.
Analysis of sequences. The 5 UTR sequences of hepatitis C virus obtained
from the samples were aligned with reported HCV genotypes using CLUSTAL
W version 1.82. Briefly, the sequences in FASTA format were pasted in the
submission form (available at http://www.ebi.ac.uk/clustalw/), and the output
obtained was represented by a phylogenetic tree. The NCBI accession numbers
of the representative HCV genotypes used for comparative analysis were as
follows: 1a, M62321; 1b, D11355; 1c, D14853; 2a, D00944; 2b, D10988; 3a,
D28917; 3b, D49374; 4a, Y11604; 5a, Y13184; and 6a, Y12083.
Statistical analysis. The values representing the enzymatic activities of ALT,
AST, and ALP, obtained from the patients before and after interferon treatment,
were statistically analyzed using the Student t test. All tests of significance were
two tailed, with P values of less than 0.05, which was considered to be statistically
significant.
Nucleotide sequence accession numbers. The nucleotide sequence data re-
ported here have been submitted to the GenBank nucleotide sequence database
with accession numbers from DQ140282 to DQ140341 as follows: 5UTR before
treatment (BT), samples 1 to 14, DQ140282 to DQ140295, and sample 15,
DQ140301; 5 UTR after treatment (AT), samples 16 to 20, DQ140296 to
DQ140300; PePHD BT, samples 1 to 15, DQ140302 to DQ140315, and sample
10, DQ140321; PePHD AT, samples 16 to 20, DQ140316 to DQ140320; ISDR
BT, samples 1 to 15, DQ140322 to DQ140336; and ISDR AT, samples 16 to 20,
DQ140337 to DQ140341.
RESULTS
Levels of viremia in patients undergoing treatment. In order
to have comprehensive information about the molecular basis
of the responses to interferon therapy during HCV infection in
the Indian population, a random group of 15 patients were
selected for our study. The group consisted of 14 males and
1 female. Different patients had different routes of infection,
through blood transfusion, surgery, and unhygienic habits
(Table 1).
The response to interferon-based therapy was primarily mon-
itored by measuring the viral loads at the beginning and during
the course of treatment. Viral RNAs were isolated from the
infected serum and were quantitated with the help of a commer-
cially available quantitation kit, the COBAS AMPLICOR HCV
Monitor Test version 2.0. The viral loads in the selected patient
group were found to be between 5.20 and 6.13 log10 IU/ml at the
beginning of interferon treatment (Table 2).
An SVR was observed in 10/15 patients after 24 weeks of
treatment in which the viral load fell below a detectable level
(the lower detection limit of the kit is 600 IU/ml; 2.77 log10
TABLE 1. Clinical profile of patients
Parameter Value
No. of patients ..................................................................... 15
Age (yr) ................................................................................43.86  15.04
Sex (no. of patients/total)
Female .............................................................................. 1/15
Male .................................................................................. 14/15
Route of infection (no. of patients)
Accidental needle prick.................................................. 1
Unhygienic habits ............................................................ 2
Blood transfusion ............................................................ 3
Surgery.............................................................................. 3
Unsterilized needle use .................................................. 2
Unknown .......................................................................... 4
Mode of detection (no. of patients/total)
ELISAa ............................................................................. 15/15
PCR................................................................................... 15/15
a ELISA, enzyme-linked immunosorbent assay.
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IU/ml) (Fig. 1). Although in some patients (4/10) the response
was faster and the viral load fell below the detectable limit
(BDL) within 4 weeks of treatment, in other cases (6/10) the
response was relatively slow and the viral RNA was detectable
up to 16 weeks of treatment (Fig. 1). However, in the case of
nonresponders, HCV RNA was detectable throughout treat-
ment, while after treatment the virus load was found to be only
marginally reduced from 5.67 to 5.38 log10 IU/ml (Fig. 1).
Estimation of the ALT enzyme level before treatment showed
considerably higher values compared to a healthy control (5 to
40 U/liter). The mean value in responders was estimated to be
59.4  31.37 U/liter at the beginning of treatment, which even-
tually fell after treatment to 24.7  9.16 U/liter, which is within
the normal range. Similarly, in nonresponders, the mean value
was found to be 89.2  31.2 U/liter before treatment, which
was reduced to 37.2  16.25 U/liter after treatment. However,
an abnormally high ALT level was observed with the genotype
1 infection (samples 3, 4, 7, 10, 11, 13, and 14) compared to
samples of other genotypes.
Similarly, estimation of the AST level showed the mean
value for the responders to be 63.8  9.6 U/liter, and that for
nonresponders was 105  57.58 U/liter before treatment.
However, in both cases, the enzyme levels were reduced to a
normal level after treatment: responders showed 27  10.4
U/liter, and for nonresponders it was 41.4  18.9 U/liter. An
abnormally high AST level (normal value, 5 to 40 U/liter) was
found to be associated with type 1 infection before treatment.
The ALP level was also estimated both before and after
treatment for responders and nonresponders, but the values
did not show significant changes after treatment (Table 2). For
the responders, the mean value before treatment was esti-
mated to be 287  66.6 U/liter, which became 266.8  4.3
U/liter after treatment. For the nonresponders, the mean value
was 290  36.2 U/liter, which was reduced to 247  41.29
U/liter after treatment. Considering that the normal ALP level
is 60 to 306 U/liter, the values were not abnormally high or out
of range. Thus, these marginal changes in level during treat-
ment did not seem to reflect the response pattern.
Student’s t test was performed for all enzyme levels (ALT,
AST, and ALP) obtained from the patients (both responder
and nonresponder) before and after treatment to check the
statistical significance. A P value of0.05 was considered to be
significant. For both groups, the values calculated for all en-
zymes (ALT, AST, and ALP) before treatment reflected con-
siderable significance compared with normal levels, whereas
there was no statistical evidence to prove that the values after
treatment were significantly different from the normal control
levels.
Influence of genotypes. In order to study the influence of the
genotype in sustained virological response to interferon treat-
ment, part of the HCV 5 UTR sequences (nucleotides 70 to
310) of all 15 samples were compared with those of the known
HCV genotypes 1, 2, 3, 4, 5, and 6, along with their subtypes.
For the phylogenetic analysis, the results were represented as
a phylogenetic tree (Fig. 2). The results suggest that 9/15 were
type 1 and 6/15 were type 3. Additionally, the percent homol-
ogy (a score table was obtained from the same phylogram
analysis) was considered in assigning the subtype for each
sample (data not shown). The results showed the presence of
FIG. 1. Virological status during treatment. Viral RNAs were es-
timated at the beginning and at different times (4, 16, and 24 weeks)
during the course of treatment and plotted as log10 values against the
time (in weeks) for responders, slow responders, and nonresponders.
TABLE 2. Clinical and virological characteristics of patients before and after therapy
Sample Genotype
Viral load
(IU/ml)
ALT level
(U/liter)
AST level
(U/liter)
ALP level
(U/liter) Response
BT AT BT AT BT AT BT AT
1 3b 1,231,000 BDL 52 28 59 19 288 220 Fast
2 3b 162,000 293,000 76 63 84 72 320 280 None
3 1a 391,000 171,000 61 42 67 47 295 228 None
4 1b 693,000 231,000 121 29 117 33 228 234 None
5 3b 282,000 BDL 44 21 51 18 292 198 Fast
6 3b 782,000 BDL 94 32 105 37 388 370 Fast
7 1a 687,000 24,100 125 31 200 29 299 196 None
8 3b 341,000 9,000 36 31 46 37 299 480 Slow
9 1a 471,000 BDL 18 18 26 26 235 197 Slow
10 1a 341,000 BDL 63 31 71 35 276 192 Slow
11 1b 706,000 313,000 63 21 58 26 310 298 None
12 3b 451,000 BDL 54 17 51 21 223 210 Slow
13 1b 373,000 BDL 81 05 93 07 403 220 Slow
14 1a 1,355,000 BDL 121 32 108 35 191 286 Slow
15 1a 231,000 BDL 31 32 28 35 281 295 Fast
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types 1a (6/15), 1b (3/15), and 3b (6/15) in our sample popu-
lation (Table 2). Interestingly, we have observed that a major-
ity (three of four) of the fast responders belonged to type 3b,
whereas the slow responders were predominantly of type 1a
(four of six). As expected, in the nonresponder group, a ma-
jority (four of five) were found to be genotype 1.
Analysis of mutations in the ISDR region of nonstructural
protein 5A. Earlier studies revealed that the NS5A protein
binds and represses the IFN-induced PKR. The PKR-interact-
ing domain of NS5A spans amino acid positions 2209 to 2249
and encompasses the ISDR. Mutations in this region are be-
lieved to partially account for different patient responses to
treatment (14). Considering the importance of this region, we
looked for mutations within the region in different patient
samples and compared the sequence with a representative
nonresponder sequence (prototype J). It was found to be
highly conserved except for some mutations, which were highly
variable. Multiple mutations were found (9/41) in the ISDR of
sample 1, which was a fast responder. However, sample 7
showed 10/41 mutations but still failed to respond to interferon
treatment (Fig. 3). The mutation frequency in the rest of the
samples was 1 or null, but there was no clear correlation with
the response pattern. To get a clearer picture, we investigated
whether the virus had undergone mutation in the ISDR region
during treatment. However, the ISDR sequences of only two
cases out of five nonresponders showed variations after treat-
ment (samples 2 and 3), whereas in the other three cases, the
sequences were found to be identical after treatment (samples
4, 7, and 11). Thus, the results were again not clear enough to
predict the effect of mutations in the ISDR on the outcome of
interferon treatment.
Analysis of the mutations in the PePHD region of the E2
envelope protein. The PePHD region of the envelope protein
was recently reported to be an important determinant in predict-
ing the interferon response in HCV-infected patients (23). Thus,
we were further interested in analyzing the mutations that af-
fected the PePHD region and in studying its possible impact on
the interferon response (3). For this, 12-amino-acid domain se-
quences (659 [position 1 {P1}] to 670 [P12]) of the PePHD
regions from 15 patient samples (before treatment) were com-
pared with the nonresponder prototype (prototype J) sequence
(Fig. 4). Although, the number of mutations (one or two) did not
vary significantly between responders and the nonresponder, cer-
tain positions (e.g., serine660 [P2]) were found to be highly sus-
ceptible to mutation and might play a role in determining the type
of response to interferon therapy. In our study, in six samples
(samples 3, 5, 9, 10, 14, and 15), the amino acid at position 660,
serine, was mutated to alanine. Interestingly, this mutation in a
majority of cases (five of six) occurred more frequently in re-
sponders than in nonresponders (one of six). Glutamic acid at
position 661 (P3) was also found to be mutated to aspartic acid in
three samples (samples 3, 5, and 15), and among these three
samples, two belong to the responder group. At position 662 (P4),
leucine was mutated to methionine in two samples, which belong
to the nonresponder group.
Further investigation of the mutations in this region after
therapy showed some interesting variations. The residue at
position 662 (P4), methionine, had reverted to leucine (the
same as prototype J) after treatment of the patient (samples 2
and 4). Similarly, in sample 7, threonine668 (P10) was found to
revert to serine (the same as prototype J) during the course of
treatment. In fact, serine at this position was found to be
FIG. 2. Phylogenetic analysis of the Indian isolates using the 5 UTR sequences. Shown is a phylogenetic tree demonstrating the genetic
relationships of different patient samples with standard HCV isolates based on the nucleotide identity of the 5 UTR (nucleotides 70 to 310). The
values of genetic distances between isolates are as follows: S1, 0.00278; S6, 0.00139; S2, 0.00313; 3a, 0.01771; 3b, 0.00635; S8, 0.00415; S5, 0.01904;
S12, 0.01013; 4a, 0.01825; 5a, 0.00939; 2a, 0.00000; 2b, 0.02083; 6a, 0.00638; S10, 0.00000; S14, 0.00000; S7, 0.00000; S13, 0.00000; S4, 0.00706; S11,
0.00000; 1b, 0.00000; 1c, 0.00196; S3, 0.00000; S9, 0.00000; S15, 0.00000; and 1a, 0.00000.
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relatively conserved in all samples. These point mutations
might have direct or indirect consequences for the phosphory-
lation of the PePHD region during HCV infection and might
influence responses during interferon therapy.
Quasispecies analysis. Viral quasispecies variation in the
otherwise-conserved 5 UTR during treatment with interferon
could also be an important determinant of the response. In
order to investigate the influence of mutations in the 5 UTR
in a single individual during treatment, the sequences of the 5
UTRs of the nonresponder samples (before and after treat-
ment) were compared with known HCV prototypes.
Among five nonresponders that were analyzed, four be-
longed to type 1 and one belonged to type 3 before treatment.
The 5 UTRs of four nonresponders who belonged to type 1
had conserved sequences with very few mutations compared
with sequences obtained after treatment. However, in sample
2, an interesting pattern was observed in which the genotype
was determined to be type 3 before treatment, but during
treatment, mutations caused it to change to type 1 (Fig. 5).
These mutations in sample 2 were found to be distributed
throughout its 5 UTR, but none of them were located in
conserved regions, which have been shown to be important for
viral translation by internal initiation (data not shown).
DISCUSSION
Several reports have demonstrated possible correlations be-
tween the mutations in the PePHD and ISDR and the inter-
feron responsiveness of HCV-infected patients worldwide.
Here, we have analyzed the clinical significance of the muta-
tions in the ISDR and the PePHD region to the response to
therapy among HCV-infected patients in India. In this study,
out of 15 patients, six samples belonged to type 1a, three
samples were type 1b, and six samples were type 3b.While 10
patients (predominantly type 3) showed complete response to
therapy, 5 of them did not respond (predominantly type 1).
Thus, the study group was comprised of both responders and
nonresponders and also included the representative prevalent
genotypes (types 1 and 3) in India.
However, the differences in the genotype did not seem to
influence the pretreatment viral load, since the viral-RNA load
ranged from 5.2 to 6.09 log10 IU/ml for samples having geno-
type 3, whereas it was 5.36 to 6.13 log10 IU/ml for samples that
belonged to type 1. Interestingly, in this study, we found that
the initial viral loads in a majority of responders (7/10) were
lower than those of the nonresponders. In the responders,
FIG. 3. Mutations within ISDR. Shown is the alignment of amino acid residues 2209 to 2249 of the ISDR of the NS5A protein obtained from
the samples and compared with the reference prototype J (nonresponder) sequence. The amino acids that are shown as superscript represent the
mutations at the respective positions observed after interferon treatment in the same nonresponder sample. In sample 2, the sequences were
compared (both AT and BT) from amino acids 2210 to 2249. The asterisk indicates insertion of two R residues in sample 8 (before treatment).
FIG. 4. Mutations within PePHD. Shown is the alignment of amino
acid residues 659 to 670 of the PePHD region of the E2 envelope
protein obtained from patient samples and compared with the refer-
ence prototype J (nonresponder) sequence. The superscript amino
acid residues represent mutations observed after interferon treatment
in the same nonresponder sample.
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the viral load was found to be steadily decreasing to below the
detectable limit after 24 weeks of treatment, along with the
enzyme level. However, in the nonresponders, the initial viral
load was relatively high, and during treatment the viral load
was found to fluctuate, albeit marginally (data not shown), and
it was not reduced significantly after 24 weeks of therapy,
although in some cases (samples 3, 4, 7, and 11) the enzyme
levels were found to return to normal level.
In sample 1, we found nine mutations in the ISDR, and the
patient showed fast response to interferon therapy. On the
other hand, in sample 7, 10 mutations in the ISDR were no-
ticed, but the patient did not respond to interferon at all. Other
samples showed at most one or two mutations that did not
correlate with the response pattern. In fact, earlier studies also
demonstrated that the correlation between mutations in the
ISDR and interferon responsiveness was observed only with
the J group (an HCV 1b isolate in Japan) (14), but similar
correlations were not observed in studies conducted in Europe
and United States (11).
However, the mutations in the PePHD region could provide
better correlations of the response to interferon therapy. In
our study, the frequency of mutations was found to be highest
(six samples) at position 660 (S3A), and a majority of these
patients responded well to interferon therapy. Additionally, a
mutation at position 661 (E3D) was also found to be associ-
ated with response (two out of three samples) to some extent.
Interestingly, the histidine at position 667, which was shown
earlier to be associated with response (2), was found to be
present in sample 1 (from a complete responder) and might
influence the response to interferon treatment.
Mutations observed at positions 662 and 663 were not asso-
ciated with response, whereas a mutation at position 668 could
be associated with response, which is consistent with earlier
studies (2, 18). Additionally, in some cases, we have observed
reversion of a mutation after treatment (samples 2 and 4, M662
to L662; sample 3, A660 to S660 and D661 to E661; and sample 7,
T668 to S668), which matched the prototype J sequence and
might have contributed to resistance to interferon therapy.
The 5 UTR of HCV probably plays a role in the ability of
HCV variants to replicate in infected patients and affect the
response pattern during interferon therapy. The results of our
study showed that the 5 UTR was highly conserved in most of
the cases (four of five), and no significant sequence heteroge-
neity was observed after treatment. However, in sample 2 (one
of five), several nucleotide changes were observed after treat-
ment, which resulted in a change in its genotype from type 3b
to type 1a. In the same sample, although it initially responded
to the therapy, the viral load showed progressive increase after
the fourth week of treatment (data not shown), suggesting that
the mutations in the 5 UTR might have facilitated replication
of the virus in the infected patient. When these mutations were
plotted onto the putative secondary structure of the HCV 5
UTR, a majority of them were located in the SLIII region.
However, most of the quasispecies variations of sample 2 after
treatment were found to be in the apparently nonconserved
segment of SLIII, as we reported earlier (1), and were not
likely to affect the structure of the 5 UTR RNA (data not
shown).
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